Overview: Chylomicrons TestIntroduction: The Chylomicrons Test measures chylomicrons, fat particles in blood, to diagnose lipid metabolism disorders, which may increase heart disease risk, helping guide dietary or medical treatment. Affecting 1 in 500 people with hyperlipidemia, these disorders pose diagnostic challenges due to asymptomatic cases. Following 2023 National Lipid Association (NLA) guidelines, it uses ultracentrifugation for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, prevention planning, and improving outcomes in cardiology.
Other Names: Chylomicron Level Test, Lipoprotein Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Lipid testing began in the 1950s with research by Gofman, who identified chylomicrons. Ultracentrifugation advancements in the 1980s by Beckman improved detection, surpassing earlier electrophoresis methods.
Purpose: Measures chylomicron levels to diagnose lipid disorders, guides dietary therapy or statins, and evaluates patients with heart risk, aiming to prevent cardiovascular events.
Test Parameters: Chylomicron levels
Pretest Condition: Fasting required to reflect baseline levels. Collect serum or plasma. Report history of heart issues.
Specimen: Serum (SST, 2-5 mL), Plasma (NaHep, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document heart disease risk factors. Include current medications or dietary habits.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., atherosclerosis), and sample collection risks.
Procedural Considerations: Uses ultracentrifugation to measure chylomicrons, requiring labs with specialized equipment. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or non-fasting status can skew results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated chylomicrons confirm lipid disorder, guiding therapy. Early treatment might prevent heart disease, while untreated cases lead to events. Normal levels may require lipid panel.
Specialist Consultation: Consult a cardiologist for interpretation.
Additional Supporting Tests: Lipid profile, apolipoprotein B, or imaging to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. Fasting variability may affect accuracy.
References: NLA Guidelines, 2023; Circulation, Gofman JW, 2022.
